Revvity, Inc. announced a partnership with Eli Lilly and Company that will make Lilly’s TuneLab AI‑driven predictive models available through Revvity’s Signals Xynthetica platform. The collaboration creates a federated framework that lets biopharmaceutical companies access advanced AI/ML models while contributing data to improve model performance without sharing raw data, thereby preserving privacy and regulatory compliance.
The deal positions Revvity to accelerate AI‑enabled drug discovery for participating biotechs. By integrating TuneLab into its Signals ecosystem, Revvity will offer secure, privacy‑preserving access to high‑quality predictive models and enable users to contribute data that refines model accuracy through federated learning. The partnership also includes joint funding for selected biotechs, providing software and modeling credits to lower barriers to AI adoption in the biotech sector.
Eli Lilly’s TuneLab, launched in September 2025, has already been leveraged by other partners such as Circle Pharma. Revvity’s Signals Xynthetica platform is designed to deliver AI models across the drug‑discovery workflow, from early target identification to preclinical development. The partnership expands Revvity’s portfolio and strengthens its competitive standing in the life‑sciences informatics market, where AI adoption is accelerating.
Market reaction to the announcement was positive. Revvity’s shares rose sharply on the day of the announcement, reflecting investor enthusiasm for the expanded AI capabilities and the potential for new revenue streams from biopharma customers. Analysts noted that the partnership could drive higher utilization of Revvity’s platform and open new cross‑sell opportunities with Lilly’s existing customer base.
Management emphasized the strategic fit of the collaboration. Revvity’s CEO highlighted that the partnership “aligns with our mission to democratize AI in drug discovery and unlock value for our customers by combining our platform’s scalability with Lilly’s world‑class predictive models.” Eli Lilly’s leadership echoed the sentiment, underscoring the importance of federated learning for data‑driven innovation while maintaining data privacy.
The partnership is expected to generate incremental revenue for Revvity in the coming years, as biotechs adopt the integrated platform and contribute data that improves model performance. The joint funding initiative is designed to accelerate adoption and create a virtuous cycle of data enrichment and model refinement, positioning Revvity to capture a larger share of the growing AI‑driven drug‑discovery market.
The content on BeyondSPX is for informational purposes only and should not be construed as financial or investment advice. We are not financial advisors. Consult with a qualified professional before making any investment decisions. Any actions you take based on information from this site are solely at your own risk.